Background: - Diabetes Mellitus (DM) is a group of metabolic diseases characterized byrnhyperglycemia with disturbances of carbohydrates, fat and protein metabolism resulting fromrninsufficient insulin secretion, defects in insulin secretion, insulin action, or both. Individuals withrntype 2 diabetes have a higher incidence of liver function abnormalities. In this study we assess liverrnfunction tests in patients with type 2 diabetes mellitus who are receiving different anti- diabetic drugsrnand we examine factors associated with these biochemical changes.rnObjective: - To investigate profile of liver function tests among type 2 diabetic patients who arernreceiving different anti-diabetic drugs attending Tikur Anbessa Specialized Hospital.rnMethods: - Hospital based cross-sectional study was conducted on 70 type 2 diabetic patients whornare receiving different anti-diabetic drugs and 35 type 2 diabetic patients who do not receive anyrnmedication were recruited for this study. The blood was taken at the fasting period and liverrnenzymes, total protein (TP), albumin (AL), total bilirubin (TB), fasting blood sugar (FBS), lipidrnprofiles and body mass index (BMI) were carried out in all patients and control group following thernstandard procedures.rnResults: Mean values of alkaline phosphatase (ALP), albumin (AL), TP and FBS were significantlyrnhigher in type 2 diabetic patients receiving different anti-diabetic drugs than in control group. Inrncontrast, mean value of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)rnamong study group were lower than control group. Mean values of TC and LDL were lower in studyrngroup than in the control group. The mean value differences between the study group and control ofrnTB, TG and HDL were statistically not significant. There are no significant differences of liverrnenzymes, TP, AL, TB, and lipid profiles in different patients who were on different anti-diabeticrndrugs. But mean value of liver enzymes and lipid profiles were slightly lowered in patients receivingrnmono therapy of insulin and metformin than insulin plus metformin, whereas BMI and FBS werernlowered in their combination therapy receiving group. Similarly mean value of FBS, ALT, TC, HDL,rnLDL and lipid profiles were lowered in patients receiving mono therapy of glibenclamide andrnmetformin than glibenclamide plus metformin combination therapy receiving group, while BMI andrnTB were increased in patients receiving mono therapy of metformin and glibenclamide.rnConclusion: The anti-diabetic drugs were found to have an effect in lowering liver enzymes andrnlipid profiles in type 2 diabetic patients. The different biochemical parameters tested were more orrnless similar in different groups of individuals who were on different anti-diabetic drugs of monorntherapy or combination therapy.rnKeywords: - LFT; Alkaline phosphatase; Lipid profile; Aminotransferases (ALT & AST)